Silence Therapeutics plc (SLN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Silence Therapeutics plc (SLN) trades at $7.82 with AI Score 58/100 (Grade B). Silence Therapeutics plc is a biotechnology company specializing in RNA therapeutics for hematology, cardiovascular, and metabolic diseases. Market cap: 370M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for SLN: SLN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SLN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SLN: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
Silence Therapeutics plc (SLN) Healthcare & Pipeline Overview
Silence Therapeutics plc, a biotechnology firm based in London, focuses on pioneering RNA therapeutics using its mRNAi GOLD platform to target genes associated with hematological, cardiovascular, and metabolic disorders. The company's innovative approach positions it within the competitive biotechnology landscape, aiming to address unmet medical needs through novel RNA interference technologies.
What Is the Investment Thesis for SLN?
Silence Therapeutics presents a compelling investment thesis centered on its innovative mRNAi GOLD platform and diverse pipeline of RNA therapeutics. The company's strategic collaborations with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical validate its technology and provide financial support for ongoing research and development. Key value drivers include the successful advancement of SLN360 and SLN124 through clinical trials, with potential for significant revenue generation upon regulatory approval. The company's gross margin of 61.5% indicates strong potential profitability. Upcoming data readouts from Phase I trials of SLN360 and SLN124 are potential catalysts. However, the company's negative P/E ratio of -3.68 and a substantial negative profit margin of -15851.9% highlight the risks associated with biotechnology investments, including clinical trial failures and regulatory hurdles.
Based on FMP financials and quantitative analysis
SLN Key Highlights
- Market capitalization of $0.33 billion reflects investor valuation of Silence Therapeutics' pipeline and technology platform.
- Gross margin of 61.5% demonstrates the potential for high profitability in successful therapeutic products.
- Negative P/E ratio of -3.68 indicates the company's current lack of profitability due to ongoing R&D investments.
- Beta of 1.35 suggests higher volatility compared to the overall market, typical for biotechnology companies.
- Collaboration agreements with AstraZeneca and Mallinckrodt provide financial resources and validation of the company's RNAi technology.
Who Are SLN's Competitors?
Who Are SLN's Competitors?
SLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIU AC Immune SA | $2.83 | -0.70% | 289M | 54 |
| ALDX Aldeyra Therapeutics, Inc. | $1.75 | +4.61% | $105.56M | 43 |
| AMRN Amarin Corporation plc | $13.80 | -5.02% | 286M | 51 |
| ANRO Alto Neuroscience, Inc. | $20.88 | +0.46% | 733M | 55 |
| CAPR Capricor Therapeutics, Inc. | $34.59 | -1.28% | 2B | 48 |
| SNDX Syndax Pharmaceuticals, Inc. | $17.34 | -3.77% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $57.69 | +1.54% | $2.49B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $3.82 | -0.26% | 361M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLN's Key Strengths?
- Proprietary mRNAi GOLD platform.
- Strong intellectual property portfolio.
- Strategic collaborations with major pharmaceutical companies.
- Focus on rare and metabolic diseases.
What Are SLN's Weaknesses?
- Limited number of products currently in late-stage development.
- High reliance on collaborations for revenue generation.
- Negative profitability and high R&D expenses.
- Susceptibility to clinical trial failures.
What Could Drive SLN Stock Higher?
- Data readout from Phase I clinical trials of SLN360 for cardiovascular disease (2026).
- Data readout from Phase I clinical trials of SLN124 for non-transfusion dependent thalassemia (2026).
- Expansion of strategic collaborations with pharmaceutical companies.
- Advancement of pipeline candidates through clinical development.
- Potential for regulatory approval of SLN360 and SLN124.
What Are the Key Risks for SLN?
- Clinical trial failures and regulatory hurdles.
- Competition from other RNA therapeutics companies.
- Patent challenges and intellectual property disputes.
- High R&D expenses and negative profitability.
- Reliance on collaborations for revenue generation.
What Are the Growth Opportunities for SLN?
- Advancement of SLN360 for Cardiovascular Disease: SLN360, currently in Phase I clinical trials, targets cardiovascular disease associated with high lipoprotein levels. The cardiovascular disease market is substantial, with a global market size estimated at hundreds of billions of dollars. Successful clinical trials and subsequent regulatory approval could generate significant revenue streams for Silence Therapeutics. The timeline for potential market entry is dependent on clinical trial outcomes, with potential for commercialization within the next 3-5 years.
- Development of SLN124 for Hematological Disorders: SLN124 is being developed for the treatment of non-transfusion dependent thalassemia and myelodysplastic syndrome, both hematological disorders with unmet medical needs. The market for thalassemia and myelodysplastic syndrome treatments is growing, driven by increasing diagnosis rates and limited treatment options. Successful development and commercialization of SLN124 could provide Silence Therapeutics with a significant market share. Clinical trial data is expected in the next 1-2 years, which will be a key milestone.
- Expansion of mRNAi GOLD Platform Applications: Silence Therapeutics' mRNAi GOLD platform has the potential to be applied to a wide range of diseases beyond the current pipeline. Expanding the platform's applications through internal research and development or strategic partnerships could unlock new revenue streams and diversify the company's product portfolio. This expansion could target areas such as oncology, neurology, and infectious diseases, offering long-term growth opportunities.
- Strategic Collaborations and Licensing Agreements: Silence Therapeutics can leverage its mRNAi GOLD platform and pipeline assets through strategic collaborations and licensing agreements with larger pharmaceutical companies. These partnerships can provide upfront payments, milestone payments, and royalties on future sales, generating significant revenue and validating the company's technology. Continued focus on securing and expanding these collaborations will be crucial for long-term growth.
- Targeting Rare and Metabolic Diseases: Silence Therapeutics focuses on developing therapies for rare and metabolic diseases, which often have limited treatment options and high unmet medical needs. The market for rare disease treatments is growing, driven by increasing awareness and regulatory incentives. Successful development and commercialization of therapies for these diseases can provide Silence Therapeutics with a competitive advantage and premium pricing opportunities.
What Opportunities Does SLN Have?
- Expansion of mRNAi GOLD platform applications.
- Securing additional strategic collaborations.
- Advancement of pipeline candidates through clinical trials.
- Targeting new rare and metabolic diseases.
What Threats Does SLN Face?
- Competition from other RNA therapeutics companies.
- Clinical trial failures and regulatory hurdles.
- Patent challenges and intellectual property disputes.
- Changes in healthcare regulations and reimbursement policies.
What Are SLN's Competitive Advantages?
- Proprietary mRNAi GOLD platform for targeted RNA interference.
- Strong intellectual property portfolio protecting its RNA therapeutic technologies.
- Strategic collaborations with major pharmaceutical companies.
- Focus on rare and metabolic diseases with high unmet medical needs.
What Does SLN Do?
Silence Therapeutics plc, formerly SR Pharma plc, was rebranded in May 2007 to reflect its focus on silencing disease-causing genes through RNA interference. The company is dedicated to the discovery and development of novel RNA therapeutics, primarily targeting hematology, cardiovascular diseases, and rare metabolic indications. Its core technology, the mRNAi GalNAc Oligonucleotide Discovery (GOLD) platform, enables precise targeting of disease-associated genes within the liver. This platform designs short interfering RNA (siRNA) molecules that leverage the body's natural RNA interference mechanism to degrade messenger RNA (mRNA) molecules, effectively silencing the production of specific disease-associated proteins. Silence Therapeutics is advancing a pipeline of product candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease linked to high lipoprotein levels. SLN124 is also in Phase I trials for non-transfusion dependent thalassemia and myelodysplastic syndrome, with plans to explore its potential in treating polycythemia vera. The company has established strategic collaborations with AstraZeneca PLC to develop siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases, as well as with Mallinckrodt Pharma IP Trading DAC to target the complement cascade in complement-mediated disorders. A collaboration with Hansoh Pharmaceutical Group Company Limited focuses on developing siRNAs for three undisclosed targets using Silence's mRNAi GOLD platform. Headquartered in London, United Kingdom, Silence Therapeutics aims to transform the treatment landscape for diseases with limited therapeutic options.
What Products and Services Does SLN Offer?
- Develops RNA therapeutics for various diseases.
- Utilizes mRNAi GOLD platform to target specific disease-associated genes.
- Designs short interfering RNA (siRNA) molecules.
- Focuses on hematology, cardiovascular, and metabolic indications.
- Conducts clinical trials for product candidates like SLN360 and SLN124.
- Collaborates with pharmaceutical companies for drug development and commercialization.
How Does SLN Make Money?
- Develops and patents RNA therapeutic technologies.
- Out-licenses technology and drug candidates to larger pharmaceutical companies.
- Generates revenue through upfront payments, milestone payments, and royalties from collaborations.
- Conducts internal research and development to expand its pipeline.
What Industry Does SLN Operate In?
Silence Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the RNA therapeutics market. This market is characterized by high growth potential, driven by advancements in gene silencing technologies and the increasing prevalence of genetic diseases. The competitive landscape includes companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which are also developing RNAi-based therapies. Silence Therapeutics differentiates itself through its mRNAi GOLD platform and strategic collaborations. The global RNA therapeutics market is projected to reach billions of dollars in the coming years, offering significant opportunities for companies with innovative technologies.
Who Are SLN's Key Customers?
- AstraZeneca PLC (collaboration partner)
- Mallinckrodt Pharma IP Trading DAC (collaboration partner)
- Hansoh Pharmaceutical Group Company Limited (collaboration partner)
- Patients with hematological, cardiovascular, and metabolic diseases
SLN Financials
SLN Latest News
-
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
zacks.com · Apr 16, 2026
-
European Equities Traded in the US as ADRs Rise in Tuesday Trading
MT Newswires · Apr 14, 2026
-
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
MT Newswires · Apr 10, 2026
-
Earnings Scheduled For February 27, 2025
benzinga · Feb 27, 2025
SLN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLN.
Price Targets
Wall Street price target analysis for SLN.
SLN MoonshotScore
What does this score mean?
The MoonshotScore rates SLN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are SLN's Competitors?
Latest News
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
European Equities Traded in the US as ADRs Rise in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Earnings Scheduled For February 27, 2025
Leadership: Iain Gladstone Ross
CEO
Iain Gladstone Ross serves as the CEO of Silence Therapeutics plc. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Silence Therapeutics, he held leadership positions at various companies, focusing on corporate strategy, business development, and commercial operations. His expertise spans across multiple therapeutic areas, including cardiovascular, metabolic, and rare diseases. He is responsible for overseeing the company's strategic direction, pipeline development, and partnerships.
Track Record: Under Iain Gladstone Ross's leadership, Silence Therapeutics has focused on advancing its mRNAi GOLD platform and expanding its pipeline of RNA therapeutics. Key achievements include securing strategic collaborations with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical, as well as progressing SLN360 and SLN124 through clinical trials. He has also overseen the company's efforts to strengthen its intellectual property portfolio and expand its focus on rare and metabolic diseases.
Silence Therapeutics plc ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Silence Therapeutics (SLN), as an ADR, it allows U.S. investors to buy shares in the company without the complexities of cross-border transactions. Each SLN ADR represents a specific number of Silence Therapeutics' ordinary shares traded on its home market.
- Home Market Ticker: London Stock Exchange, United Kingdom
- ADR Level: 2
- ADR Ratio: 1:1
Silence Therapeutics plc Healthcare Stock: Key Questions Answered
What does Silence Therapeutics plc do?
Silence Therapeutics plc is a biotechnology company focused on developing RNA therapeutics for various diseases. The company's core technology is its mRNAi GOLD platform, which enables the design of short interfering RNA (siRNA) molecules that target specific disease-associated genes. These siRNAs silence the production of proteins that contribute to disease, offering a novel approach to treating conditions with unmet medical needs. The company's pipeline includes product candidates targeting hematological, cardiovascular, and metabolic disorders.
What do analysts say about SLN stock?
Analyst coverage of Silence Therapeutics is limited, reflecting its status as a smaller biotechnology company with a focus on early-stage clinical development. Key valuation metrics include market capitalization and potential revenue from future product sales. Growth considerations center on the successful advancement of pipeline candidates through clinical trials and the expansion of strategic collaborations. Analyst consensus is not readily available, but investors should monitor clinical trial data and regulatory milestones as key drivers of stock performance. The company's high gross margin of 61.5% suggests strong potential profitability if products reach the market.
What are the main risks for SLN?
The main risks for Silence Therapeutics include the inherent uncertainties of clinical development, such as the potential for clinical trial failures and regulatory hurdles. Competition from other RNA therapeutics companies also poses a risk. Patent challenges and intellectual property disputes could impact the company's ability to protect its technologies. Additionally, Silence Therapeutics faces financial risks associated with high R&D expenses and negative profitability, as well as reliance on collaborations for revenue generation. These factors could impact the company's ability to fund its operations and achieve its strategic goals.
What are the key factors to evaluate for SLN?
Silence Therapeutics plc (SLN) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary mRNAi GOLD platform. Primary risk to monitor: Clinical trial failures and regulatory hurdles. This is not financial advice.
How frequently does SLN data refresh on this page?
SLN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SLN's recent stock price performance?
Recent price movement in Silence Therapeutics plc (SLN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary mRNAi GOLD platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SLN overvalued or undervalued right now?
Determining whether Silence Therapeutics plc (SLN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SLN?
Before investing in Silence Therapeutics plc (SLN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.